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CONCLUSION: The ICER for the maraviroc strategy is com-
parable to values reported for use of antiretrovirals in similar
populations, and was most favorable for individuals with few
active treatment options.
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OBJECTIVE: Nosocomial pneumonia (NP), the second most
common hospital-acquired infection in the US, is associated
with excess morbidity, mortality, hospital days and health care
costs. The objective of this study was to compare treatment
costs and cost-effectiveness of doripenem (currently under FDA
review for NP indication) to two common NP treatments.
METHODS: Outcomes for a population of hospitalized
patients with NP, including a subset of ventilator-associated
pneumonia (VAP) patients were modeled. Patients were
assumed to be treated with doripenem, imipenem or
piperacillin/tazobactam as ﬁrst-line therapy for NP. Clinical
cure and utilization data, including receipt of concomitant
medications (vancomycin/amikacin), days on mechanical venti-
lation (MV), ICU days, and LOS in hospital, were estimated
by combining data from two randomized, multicenter, non-
inferiority clinical trials of doripenem. Wholesale acquisition
costs were used for study drug; costs of MV, ICU and ward
days were estimated from published literature. The primary
outcomes were total costs and incremental cost per clinical
cure. Robustness of the baseline cost-effectiveness analysis was
evaluated using one-way and probabilistic sensitivity analyses
(PSA). RESULTS: In base-case analyses, initial treatment with
doripenem was least costly at $42,041/treated patient, followed
by piperacillin/tazobactam ($43,743), and imipenem ($44,834).
Doripenem dominated piperacillin/tazobactam by being less
costly with a higher probability of clinical cure (72.3% vs.
67.8%). Imipenem had a clinical cure rate of 72.6%, but at an
additional cost of $992,200/cure. Results among the subset of
VAP patients were similar. One-way sensitivity analyses show
the model to be most sensitive to changes in the probability of
cure with each therapy. Probabilistic sensitivity analysis results
indicate that doripenem is cost saving versus imipenem in
77.1% and versus piperacillin/tazobactam in 70.6% of 1,000
iterations. CONCLUSION: First-line therapy with doripenem
yields lower costs and similar efﬁcacy compared to common
NP treatments. Doripenem is a cost-effective treatment for NP
versus imipenem and piperacillin/tazobactam.
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OBJECTIVE: To assess differences in serial mean utility scores,
from Health Utilities Index (HUI) Mark 3 (HUI3) measurements
for patients undergoing treatment for acute lymphoblastic leuke-
mia (ALL) in childhood. These scores will be used for identifying
determinants of health. METHODS: Patients were aged 5 years
or older at time of health-related quality of life (HRQL) survey
and enrolled in the Dana Farber Cancer Institute 95–001 clinical
trial. Parents-of-patients completed self-administered HUI ques-
tionnaires during the four major phases of treatment: induction
of remission (t1); CNS prophylaxis (t2); intensiﬁcation (t3); and
maintenance (t4). HRQL scores are on a scale where 0.00 equals
dead and 1.00 equals perfect health. Signiﬁcant differences
between treatment phases, for mean HRQL and single-attribute
utility scores, were assessed using 1-way ANOVA and paired
t-test. Magnitude of change in mean HRQL scores between
treatment phases was assessed by effect size. Differences in mean
HRQL scores of >0.03 are clinically important. RESULTS: A
total of 375 patients were surveyed (55.2% males). Patients with
complete sets of parental measurements at all treatment phases
were included in this analysis (n = 86). Mean HRQL score
at t1 = 0.68 (SD = 0.306), t2 = 0.74 (SD = 0.245), t3 = 0.77
(SD = 0.267), and t4 = 0.88 (SD = 0.204) (p < 0.001). There was
substantial inter-patient variability in HRQL scores within treat-
ment phases. The effect sizes were 0.200 for t2-t1, 0.120 for t3-t2
and 0.395 for t4-t3. Mean HRQL change scores were 0.06 for t1
to t2 (p = 0.085), 0.03 for t2 to t3 (p = 0.416), and 0.10 for t3 to
t4 (p = 0.001). For single-attribute scores signiﬁcant differences
between treatment phases were observed for ambulation
(p < 0.001), emotion (p < 0.001), pain (p < 0.001). CONCLU-
SION: Mean HRQL, ambulation, emotion and pain scores gen-
erally improved over time. The large inter-patient variability may
reﬂect, in part, the considerable heterogeneity of treatment-
related side effects among patients. Further analyses will explore
whether demographic or diagnostic risk factors contribute to this
variability.
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OBJECTIVE: Research has shown that the individuals with
diabetes have a higher chance of being depressed compared to
those without diabetes. To provide effective interventions for
diabetes with depression, practitioners need a reliable and valid
instrument to examine patients’ levels of depression. The
purpose of the study was to evaluate the psychometric proper-
ties of the Patient Health Questionnaire (PHQ) in 2006 Behav-
ioral Risk Factor Surveillance System (BRFSS). METHODS:
The BRFSS is an on-going telephone health survey system,
recording U.S. adults’ health and risk behaviors yearly. The
PHQ measures the depressive symptom that subjects have had
over the last two weeks. In the current investigation, only
Washington residents who were under diabetic treatment(s)
and completed the questionnaire were included in the analyses.
Of 750 subjects in the analyses, 338 (45.07%) were male and
412 (54.93%) were female. The average age was 63.18 years
(SD = 12.53). The split-half, cross-validation method was
applied to assess the psychometric properties of the PHQ.
RESULTS: Exploratory factor analysis was ﬁrst conducted to
determine the measurement structure with the ﬁrst half of the
sample on the ﬁrst step. A one-component solution was
obtained. All items loaded heavily on the target component.
Cronbach coefﬁcient Alpha was 0.82, suggesting good internal
consistency. The second step involved an examination of the
cross-validation of the measurement structures from ﬁrst step
with the second half of the sample using conﬁrmatory factor
analysis procedures. The one-factor model ﬁtted the data well,
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c2(20) = 96.73, CFI = 0.90, GFI = 0.94, RMSEA = 0.10. The
results indicated that the “felt down, depressed or hopeless”
item was the most reliable indicator of the PHQ. CONCLU-
SION: Results provided the evidence of the reliability and
validity of the PHQ. The measure may be useful for screening,
developing and tailoring interventions to the diabetic individu-
als’ level of depression.
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OBJECTIVE: To assess the burden of uncontrolled asthma (UA)
on HRQOL of the child and their family. METHODS: An
internet-based survey was administered to caregivers of children
aged 6–12 years with moderate to severe asthma (severity
and control based on NAEPP guidelines). The caregiver question-
naire assessed pediatric asthma symptoms, rescue medication
use, activity limitation, and included the Child Health
Questionnaire—Parent Form 28 (CHQ-PF28), a generic instru-
ment measuring HRQOL in children and their family. Mean
CHQ-PF28 scores were calculated (ranging from 0–100, with
lower scores representing greater impairment) and compared
between UA and controlled asthma (CA) groups using the two-
sample t-test. RESULTS: A total of 4,514 of 16,396 invited to
participate responded. A total of 473 satisﬁed study inclusion
criteria; 360 were caregivers of children with UA and 113 for
children with CA. Seven out of 8 child-related CHQ-PF28 scale
scores were signiﬁcantly lower among children with UA versus
CA with the greatest differences in physical functioning
(mean difference = 26.8, P < 0.0001) and physical role limita-
tions (mean difference = 20.0, P < 0.0001). Physical (mean
difference = 11.7, P < 0.0001) and psychosocial (mean differ-
ence = 5.6, P < 0.0001) summary scales were both signiﬁcantly
lower among children with UA. Caregivers of children with UA
had signiﬁcantly lower scores on both parent-related scales of
emotional (mean difference = 20.8, P < 0.0001) and time (mean
difference = 16.3, P < 0.0001) impact, and 1 of 2 family-related
scales (activities, mean difference = 19.3, P < 0.0001). CON-
CLUSION: Uncontrolled asthma was associated with signiﬁcant
impairment in HRQOL, extending beyond the physical health of
the child to their psychosocial development. Additionally, uncon-
trolled pediatric asthma had a signiﬁcant HRQOL impact on the
caregiver and family.
PR4
EVALUATION OF IMPACT OF ORALTOPOTECAN ON
HEALTH-RELATED QUALITY OF LIFE IN RELAPSED SMALL
CELL LUNG CANCER
Duh MS1, Pickard AS2, Chen L1,Antras L1, Cella D3, Neary MP4,
O’Brien ME5
1Analysis Group, Inc, Boston, MA, USA, 2College of Pharmacy,
University of Illinois at Chicago, Chicago, IL, USA, 3Evanston
Northwestern Healthcare, Evanston, IL, USA, 4GlaxoSmithKline,
Collegeville, PA, USA, 5Royal Marsden Hospital, Sutton, UK
OBJECTIVE: Relapsed small cell lung cancer (SCLC) carries a
poor prognosis and is associated with poor health-related
quality of life (HRQoL). This study assesses the impact of oral
topotecan (OT) on HRQoL when used as second-line treatment
for relapsed SCLC. METHODS: Data from a randomized,
open-label, multicenter clinical trial were analyzed, including
141 patients with relapsed SCLC receiving either OT plus best
supportive care (BSC) or BSC alone. EQ-5D, a widely used
measure of HRQoL that produces both a visual analogue scale
(VAS) and an index-based utility score, was administered at
baseline and subsequently at three-week intervals. Changes in
HRQoL from baseline were compared between two groups by
measuring 1) changes between baseline and last evaluation, and
2) changes between baseline and all on-treatment evaluations
(pooled analysis). Published criteria for interpretation of mini-
mally important differences (MID) in cancer, i.e., UK-based
utility score changes of 0.10 or more and VAS score changes of
8 or more, were used to further interpret results (Pickard AS,
et al. HQLO, 2007). RESULTS: Patients receiving OT + BSC
experienced better HRQoL outcomes compared to patients
receiving BSC alone. Mean declines from baseline to the last
evaluation were signiﬁcantly smaller in the OT + BSC than BSC
alone group in EQ-5D utility (-0.10 vs. -0.30, p = 0.0078) and
VAS (-3.98 vs. -14.46, p = 0.0044) scores. Similarly, in the
pooled analysis, the OT + BSC group exhibited signiﬁcantly
smaller declines from baseline than the BSC alone group in both
EQ-5D utility (-0.04 vs. -0.18, p = 0.0045) and VAS (-0.71 vs.
-8.83, p = 0.0035) scores. Using previously established criteria
for MIDs, the differences in HRQoL decline between two groups
were statistically signiﬁcant and clinically meaningful. CON-
CLUSION: Patients receiving OT + BSC experienced smaller
declines in HRQoL from baseline than patients receiving BSC
alone. Differences in change from baseline between groups
exceeded MIDs from previous studies, indicating a meaningful
clinical beneﬁt.
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OBJECTIVE: To estimate the burden of exposure to medications
associated with known or suspected risk of fetal harm among
pregnant women in Regione Emilia-Romagna (RER), Italy.
METHODS: A prevalence study was conducted using the RER
health care database, including data for the entire RER popu-
lation of about 4 million inhabitants. Female residents of RER
who delivered a baby in a hospital between January 1, 2004
and December 31, 2004 were identiﬁed via ICD-9-CM codes.
All prescription drug data were reviewed for the 270 days
leading up to date of delivery. Drugs were grouped into preg-
nancy risk categories (A, B, C, D, X) using established classi-
ﬁcation systems. Contraindicated drugs were deﬁned as
category X drugs and potentially dangerous drugs were deﬁned
as category D drugs. Women exposed to contraindicated and
potentially dangerous drugs in the 270 days prior to delivery
were identiﬁed. RESULTS: Among the 33,343 deliveries iden-
tiﬁed in 2004, 70% were exposed to at least one prescription
medication in the 270 days prior to delivery. Approximately
1% of women were exposed to drugs contraindicated in preg-
nancy (category X), including 189 women (0.6%) receiving
these drugs during the ﬁrst trimester. Approximately 1.5% of
women were exposed to potentially dangerous (category D)
drugs. Measurable proportions of women were exposed to
ACE-inhibitors (0.79%) and HMG-CoA reductase inhibitors
(0.28%), which have recently been linked to risk of fetal mal-
formations. CONCLUSIONS: For the entire RER population,
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